Regulation Could Cut Time to Clinical Trials in Brazil

International Pharmaceutical Regulatory Monitor
A A
Drugmakers could see their wait time to begin clinical trials in Brazil cut by more than a third under a proposed regulation calling for protocols to be reviewed in their entirety, rather in stages, which is the current policy.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00